Zevra Therapeutics (ZVRA.US) Presents Positive Real-World Data for MIPLYFFA® in NPC at WORLDSymposium™

Zevra Therapeutics, Inc. (Nasdaq: ZVRA) announced positive data regarding its drug, MIPLYFFA® (arimoclomol), for the treatment of C-type Niemann-Pick disease (NPC) at the 22nd Annual WORLDSymposium™ on February 4, 2026. The company presented four posters detailing the latest real-world data on the drug’s impact on patients.

MIPLYFFA® Shows Promise in Stabilizing Disease Progression

According to Zevra, the data highlights MIPLYFFA’s potential to stabilize disease progression in a broad range of NPC patients, including adults who have historically been underrepresented in clinical data. Zevra’s Chief Medical Officer, Adrian Quartel, FFPM, stated that the data supports the drug’s benefits across a wider patient population.

Did You Know? Four years of real-world data tracking MIPLYFFA in rare Niemann-Pick disease was presented at the symposium.

Key Data Highlights

One poster, titled “Arimoclomol in NPC patients: Real-world safety and effectiveness from the US Early Access programme (EAP) – 4 year outcomes,” presented four years of data showing that arimoclomol was well-tolerated and stabilized disease progression in patients participating in the US EAP. Another poster detailed long-term therapeutic effects observed in patients participating in the EAP for up to four years.

Data from a post-hoc analysis of the NPC002 trial indicated that the combination of arimoclomol and miglustat showed a significant delay in disease progression compared to placebo after three months, with benefits increasing over 12 months. A final poster focused on the long-term safety and effectiveness of arimoclomol in adult and pediatric patients with NPC in the US EAP, showing disease stabilization over four years with a good safety profile.

Expert Insight: The presentation of four years of real-world data, including findings related to adult patients, suggests a growing body of evidence supporting the potential of MIPLYFFA to address a significant unmet need in the treatment of NPC.

Zevra Therapeutics is a commercial-stage company focused on providing therapies for rare disease patients. The company’s CFO is set to step down effective December 31, 2025, as the search for a replacement begins.

Frequently Asked Questions

What is Niemann-Pick disease Type C?

Niemann-Pick disease Type C (NPC) is a rare, progressive genetic disorder.

What is MIPLYFFA®?

MIPLYFFA® (arimoclomol) is a drug developed by Zevra Therapeutics for the treatment of C-type Niemann-Pick disease (NPC).

Where were these findings presented?

The data was presented at the 22nd Annual WORLDSymposium™ on February 4, 2026.

As more real-world data emerges, how might the understanding of MIPLYFFA’s long-term effects on NPC patients evolve?